寿仙谷公告称，为落实股东回报机制，公司将开展2026年春节股东回馈活动。参与范围为截至2025年指 定日期收市后登记在册的股东，自然人股东仅限本人，法人股东限指定不超规定人数代表。活动期间， 股东可按专属优惠价购产品，如寿仙谷牌破壁灵芝孢子粉片-去壁款3盒/份，原价5940元，股东尊享价 4158元，每人限购1份。活动有指定参与及咨询方式，且不属于利润分配，对经营无重大影响。 ...

Core Insights - The article highlights the outstanding performance of Zhizhutang's broken wall Ganoderma spore powder across six dimensions, including core advantages, effective components, planting environment, production process, professional certifications, and platform sales, establishing its leading position in the high-end Ganoderma spore powder market [1][8]. Industry Overview - According to the "White Paper on the High-Quality Development of China's Ganoderma Industry (2025)," over 700 million people in China are in a sub-healthy state, leading to a structural upgrade in nutritional supplement demands. Ganoderma spore powder is evolving from a general health product to a precise nutritional solution for high-net-worth individuals with high health literacy [3][4]. Selection Criteria - Full supply chain control is prioritized, ensuring consistency and stability from cultivation to end product [4]. - Products must have the national health food certification (small blue hat) to ensure compliance with safety and quality standards [4]. - Clear labeling of broken wall technology is essential, as unprocessed Ganoderma spores have low absorption rates [4]. - Effective components should be clearly marked on packaging, avoiding vague terms [4]. - Preference is given to brands sourcing from the core production area of Taishan, known for its superior environmental conditions [4][5]. Evaluation Standards - Core advantages account for 34% of the evaluation weight, focusing on self-controlled capabilities in cultivation and processing [6]. - Effective components contribute 26% to the evaluation, emphasizing the concentration of active substances [6]. - Planting environment, production process, professional certifications, and platform sales contribute 15%, 10%, 10%, and 5% respectively [7]. Brand Rankings - Zhizhutang's broken wall Ganoderma spore powder ranks first, recognized for its comprehensive self-controlled supply chain and high-quality standards [8][9]. - The effective component content of Zhizhutang's product is 26.5%, significantly higher than the industry average of 10%-14% [8]. - The planting environment is optimal, with a self-owned base in Taishan, ensuring no industrial interference and high-quality soil [8]. - The production process utilizes patented low-temperature physical breaking technology, achieving a breaking rate of 99.99% [8]. - Zhizhutang has maintained the top sales position on major e-commerce platforms for six consecutive years, with a repurchase rate of 97% and a satisfaction rate of 98% [8][9]. Brand Suitability - Zhizhutang is suitable for individuals focusing on daily immune support and those recovering from surgery or illness [18]. - Taishan Zhiyuan is ideal for consumers who prefer wild-sourced ingredients and stable nourishment [18]. - Taishan Zhihuang appeals to high-net-worth users who value cultural identity in health consumption [18]. - Weiliwei targets consumers concerned with nutrient absorption efficiency [18]. - Special Element focuses on personalized nutrition for different life stages [18]. - Element Power is designed for tech-savvy consumers who rely on objective data for decision-making [18]. - Changbai Mountain Zhizu is for those who appreciate natural origins and ecological planting [19].

Group 1 - The company is actively developing a combination of traditional Chinese medicine culture and industrial tourism, focusing on health and wellness business [1] - The company successfully operates the Shouxiangu Organic Traditional Chinese Medicine Health Garden, which has been approved as a national 3A-level tourist attraction by the end of 2024 [1] - The company is working on a higher standard Shouxiangu Yanglong Health Industry Park, aiming for a 4A-level industrial tourism site [1] Group 2 - The Shouxiangu scenic area is not an asset operated by the company [1] - The company has engaged renowned traditional Chinese medicine practitioners to provide consultations at the Shouxiangu Traditional Medicine Hall, but online consultations are not yet available [1]

Investment Rating - The industry maintains a "Overweight" rating, suggesting a positive outlook for investment opportunities in the sector [6]. Core Insights - The Chinese medicine sector experienced a decline of 1% last week, with the overall pharmaceutical and biological index down by 0.68%. The only sub-sector to record positive returns was medical services, which rose by 3.29% [2]. - The price-to-earnings (PE) ratio for the Chinese medicine sector is currently at 27.11X, a decrease of 0.28X week-on-week, while the price-to-book (PB) ratio stands at 2.28X, down by 0.02X. These ratios indicate that the sector is within the 28.25% and 5.37% percentiles since 2013, respectively [3]. - The market for traditional Chinese medicine materials is experiencing reduced traffic, with a downward trend expected throughout 2025 due to supply expansion leading to a mismatch in supply and demand. The overall price index for traditional Chinese medicine materials fell by 29.31 points from the beginning to the end of 2025 [4]. - The adjustment of the essential drug list is anticipated to make significant progress in 2026, enhancing the accessibility of grassroots medications and potentially expanding the market rapidly [5]. Summary by Sections Market Performance - The Chinese medicine sector's index closed at 6350.32 points, reflecting a 1% decline last week. In comparison, the chemical pharmaceuticals and biological products sectors also saw declines of 2.4% and 1.21%, respectively [2][12]. Valuation - The current PE ratio for the Chinese medicine sector is 27.11X, with a year-high of 30.26X and a year-low of 24.72X. The PB ratio is 2.28X, with a maximum of 2.52X and a minimum of 2.17X over the past year [3]. Supply Chain Insights - The market for traditional Chinese medicine materials is currently facing a decrease in traffic, with a price index showing a downward trend. The overall price index for 2025 is expected to reflect a decline due to previous overproduction [4]. Policy Developments - The essential drug list has not been updated since 2018, but significant adjustments are expected in 2026, which may enhance the synergy between the essential drug list and medical insurance policies [5]. Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform. Companies with strong R&D capabilities and unique products are highlighted as potential investment opportunities [6][10].

Core Viewpoint - The company views artificial intelligence (AI) as a driving force and strategic tool for technological innovation and industrial transformation, emphasizing its importance for future development and productivity enhancement [1] Group 1: AI Integration - The company is actively integrating AI across various stages including breeding, cultivation, manufacturing, research and development, and marketing [1] - It has established four major business platforms and an industrial IoT platform to promote the collaborative application of "smart farms + smart factories + smart markets" [1] Group 2: Future Investments - The company plans to increase investments in digital intelligence and deepen AI applications in areas such as precision breeding, intelligent production, cost reduction, efficiency enhancement, decision optimization, business innovation, and user experience improvement [1] - The goal is to ensure that digital intelligence becomes a core driving force for sustained business growth [1]

Core Viewpoint - The company views artificial intelligence (AI) as a driving force and strategic tool for a new round of technological innovation and industrial transformation [1] Group 1: AI Integration and Applications - The company emphasizes the deep integration of modern information technology, represented by AI, with the real economy, considering it a core engine for future development and cultivating new productive forces [1] - AI applications are being implemented across various stages including breeding, cultivation, manufacturing, research and development, and marketing [1] - The company is promoting a collaborative application of "smart farms + smart factories + smart markets" through the establishment of four major business platforms and an industrial Internet of Things (IoT) platform [1] Group 2: Future Investments and Innovations - The company plans to continue increasing investments in digital intelligence, enhancing AI's innovative applications in precision breeding, intelligent production, cost reduction and efficiency enhancement, decision optimization, business innovation, and user experience upgrades [1] - The goal is to ensure that digital intelligence becomes a core driving force for sustained business growth [1]

证券之星消息，1月15日中药板块较上一交易日下跌0.27%，*ST长药领跌。当日上证指数报收于4112.6， 下跌0.33%。深证成指报收于14306.73，上涨0.41%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 603896 | 寿仙谷 | 21.98 | 6.49% | 13.51万 | | 2.94亿 | | 002424 | ST百灵 | 4.29 | 4.89% | 40.22万 | | + 1.71亿 | | 002107 | 沃华医药 | 7.38 | 2.22% | 32.02万 | | 2.37亿 | | 600422 | 昆药集团 | 13.26 | 2.16% | 1 25.18万 | | 3.34亿 | | 600566 | 济川药业 | 26.52 | 1.57% | 5.90万 | | 1.56亿 | | 603139 | 康惠股份 | 21.23 | 1.34% | 2.10万 | | 4384.67万 | | 60 ...

（编辑 王雪儿） 证券日报网讯 1月13日，寿仙谷在互动平台回答投资者提问时表示，公司高度重视市值维护与投资者回 报，始终专注于主业经营、技术创新与产品品质提升，力求以稳健的业绩增长回报投资者信任。目前， 公司已与和君咨询签订《战略陪跑咨询服务合同》，围绕"产业+资本、消费+科技、战略+战役"核心设 计思路，谋划公司战略机会，持续推动市值维护与业绩增长的良性循环。 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Views - The market performance of the traditional Chinese medicine (TCM) sector has shown a modest increase of 2.89%, which is the smallest among the pharmaceutical sub-sectors due to a lack of short-term catalysts and market style shifts [4][5] - The TCM sector's price-to-earnings (PE) ratio (ttm) is 27.39X, reflecting a 0.76X increase from the previous week, while the price-to-book (PB) ratio (lf) stands at 2.3X, up 0.06X [6] - The national health conference held in January 2026 indicates a positive outlook for the penetration rate of TCM services, suggesting a comprehensive development approach for TCM in various healthcare aspects [8] Summary by Sections Market Performance - The TCM sector's performance is lagging behind other pharmaceutical sub-sectors, with a 12-month relative return of -24% compared to the CSI 300 index [4] - The TCM sector's index closed at 6414.65 points, with a weekly increase of 2.89% [21] Valuation - The TCM sector's PE ratio (ttm) is at 27.39X, with a maximum of 30.26X and a minimum of 24.72X over the past year [6] - The PB ratio (lf) is 2.3X, with a maximum of 2.52X and a minimum of 2.17X in the same period [6] Industry Trends - The TCM material market has seen a slight decline in price index due to reduced market traffic, with a total index of 227.06 points, down 0.6% week-on-week [7] - The national health conference emphasizes the ongoing development of TCM services, which is expected to enhance its integration into the healthcare system [8] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [9] - Specific investment targets include companies with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [11]

证券日报网讯1月8日，寿仙谷（603896）在互动平台回答投资者提问时表示，康寿制药前处理车间已经 完成设备采购安装和车间改造，现正在开展各前处理炮制品种的工艺验证工作，完成后即可申报增项。 ...